Literature DB >> 26163883

Synthesis of bicoumarin thiophosphate derivatives as steroid sulfatase inhibitors.

Sebastian Demkowicz1, Witold Kozak2, Mateusz Daśko2, Maciej Masłyk3, Bartłomiej Gielniewski3, Janusz Rachon2.   

Abstract

Based on the frameworks of 7-hydroxy-2,3-dihydro-1H-cyclopenta[c]chromen-4-one, 3-hydroxy-7,8,9,10-tetrahydro-6H-benzo[c]chromen-6-one and 3-hydroxy-8,9,10,11-tetrahydro-7H-cyclohepta[c]chromen-6-one, a series of bicoumarin thiophosphate analogs have been synthesized and biologically evaluated. Additionally, their binding modes have been modeled using docking techniques. The inhibitory properties of the synthesized compounds were tested against the STS isolated from human placenta. Most of the new STS inhibitors possessed good activities against STS. In particular, we found that the bis-(6-oxo-7,8,9,10-tetrahydro-6H-benzo[c]chromen-3-yl) hydrogenthiophosphate (10b) produced the largest inhibitory effect, with an IC50 value of 860 nM (an IC50 value of 1 μM for the 665-COUMATE used as a reference). The structure-activity relationships of the synthesized bicoumarin thiophosphate derivatives toward the STS enzyme have been discussed previously.
Copyright © 2015. Published by Elsevier Masson SAS.

Entities:  

Keywords:  Bicoumarin thiophosphates; Breast cancer; Molecular docking; STS inhibitors; Steroid sulfatase

Mesh:

Substances:

Year:  2015        PMID: 26163883     DOI: 10.1016/j.ejmech.2015.06.051

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  2 in total

Review 1.  Recent progress in the development of steroid sulphatase inhibitors - examples of the novel and most promising compounds from the last decade.

Authors:  Mateusz Daśko; Sebastian Demkowicz; Karol Biernacki; Olga Ciupak; Witold Kozak; Maciej Masłyk; Janusz Rachon
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

2.  Development of Sulfamoylated 4-(1-Phenyl-1H-1,2,3-triazol-4-yl)phenol Derivatives as Potent Steroid Sulfatase Inhibitors for Efficient Treatment of Breast Cancer.

Authors:  Karol Biernacki; Olga Ciupak; Mateusz Daśko; Janusz Rachon; Witold Kozak; Janusz Rak; Konrad Kubiński; Maciej Masłyk; Aleksandra Martyna; Magdalena Śliwka-Kaszyńska; Joanna Wietrzyk; Marta Świtalska; Alessio Nocentini; Claudiu T Supuran; Sebastian Demkowicz
Journal:  J Med Chem       Date:  2022-03-02       Impact factor: 7.446

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.